Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC:An ETCTN California cancer consortium phase I study. Riess, J. W., Groshen, S. G., Reckamp, K. L., Wakelee, H. A., Oxnard, G. R., Padda, S., Koczywas, M., Piotrowska, Z., Sholl, L. M., Paweletz, C. P., Lau, C. J., Kolesar, J., Mack, P. C., Moscow, J., Janne, P. A., Lara, P., Newman, E. M., Gandara, D. R. AMER SOC CLINICAL ONCOLOGY. 2019

View details for Web of Science ID 000487345806498